Group 1 - China Biopharmaceutical (01177) shares rose over 5%, currently up 4.92% at HKD 7.24, with a trading volume of HKD 303 million [1] - The company announced a full acquisition of Hejiya, with the deal set to close on January 13, 2026, for a maximum base price of RMB 12 million, payable in cash and shares [1] - Hejiya specializes in the research and development of small interfering RNA (siRNA) innovative drugs, focusing on chronic diseases such as metabolic disorders, cardiovascular diseases, and neurological conditions [1] Group 2 - Hejiya has developed a differentiated delivery platform with independent intellectual property rights, featuring the MVIP (Multi-Valent Import Platform), which is the first clinically validated liver-targeted delivery platform capable of "one injection per year" for long-lasting treatment [2] - This platform addresses adherence issues in chronic disease treatment, which is a significant challenge in the industry [2]

Core Viewpoint - China National Pharmaceutical Group announced the acquisition of domestic siRNA innovative drug company Hejia Bio for a total price of 1.2 billion RMB, marking a significant move in the small nucleic acid sector following its investment in Saintin Bio [1] Group 1: Company Overview - China National Pharmaceutical Group's stock rose over 4% in early trading, currently at 7.12 HKD with a trading volume of 134 million HKD [1] - Hejia Bio is a pioneering biopharmaceutical company focused on the research and development of small interfering RNA (siRNA) innovative drugs [1] Group 2: Strategic Importance - The acquisition of Hejia Bio represents a key strategic investment in the small nucleic acid space, following the previous investment in Saintin Bio [1] - Hejia Bio has developed an integrated drug development system from target discovery to proof of concept (POC), focusing on three major chronic disease areas: weight loss metabolism, cardiovascular and cerebrovascular, and nervous system [1] Group 3: Asset Portfolio - Hejia Bio possesses four clinical-stage assets and over ten preclinical assets, all of which have first-in-class and best-in-class potential [1]

Group 1 - The core point of the article is that China National Pharmaceutical Group (中生制药) experienced a significant increase in its stock price, rising over 4% in early trading and closing up by 3.04% at HKD 7.12 per share [1] - The trading volume for the stock reached HKD 134 million, indicating strong investor interest and activity in the market [1]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak of 2.88% and currently up by 2.52% [1][4]. Group 1: ETF Performance - The ETF's price reached a high of 0.577, with a current price of 0.569, reflecting a gain of 0.014 or 2.52% [2][6]. - The trading volume for the ETF was reported at 178,084 shares, with a turnover rate of 3.73% [6]. Group 2: Component Stocks - Notable performers among the ETF's component stocks include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1][5]. - Conversely, the stocks of Jiujiu Bio and Ascletis Pharma showed significant declines [1][5]. Group 3: Market Expectations - The JPM Healthcare Conference, held from January 12 to 15, 2026, has generated market anticipation regarding business development (BD) transaction data from Chinese innovative pharmaceutical companies, suggesting potential for increased international collaboration [6][7]. - The approval of updated labeling for the PD-1/VEGF dual antibody by the National Medical Products Administration for Kangfang Biopharma is expected to enhance treatment options for non-small cell lung cancer, indicating significant survival benefits [6][7]. Group 4: Industry Outlook - According to Western Securities, the innovative drug sector in Hong Kong is expected to maintain a structural market trend in 2026, with accelerated BD activities narrowing the price gap between Chinese and U.S. innovative drugs, leading to substantial long-term growth potential [7]. - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [7].

Group 1 - China Biopharmaceutical (01177) has seen its stock price increase by over 5%, currently trading at HKD 7.24 with a transaction volume of HKD 303 million [1] - The company announced a full acquisition of Hejia, with the deal set to close on January 13, 2026, for a maximum base price of RMB 12 million, which may be adjusted and paid partially in cash and partially in shares [1] - Upon completion of the acquisition, Hejia will become a wholly-owned subsidiary of China Biopharmaceutical [1] Group 2 - Hejia is a pioneering biopharmaceutical company focused on the research and development of small interfering RNA (siRNA) innovative drugs, with an integrated drug development system from target discovery to clinical proof of concept [2] - The strategic acquisition is expected to accelerate the group's innovation and clinical advancement in chronic disease areas, particularly in weight loss metabolism, cardiovascular, and neurological diseases [2] - Hejia has developed a differentiated delivery platform with independent intellectual property rights, including the MVIP (Multi-Valent Import Platform), which is the world's first clinically validated liver-targeted delivery platform capable of providing long-lasting treatment with "one injection per year" [2]

Market Overview - The Shanghai Composite Index opened slightly lower, while the Shenzhen Component Index, ChiNext Index, and STAR Market Index opened higher by 0.17%, 0.34%, and 0.35% respectively [1] - The Shanghai Composite Index is currently at 4138.65, down by 0.11% [2] - The Shenzhen Component Index is at 14194.11, up by 24.71 points or 0.17% [2] - The ChiNext Index is at 3333.17, up by 11.28 points or 0.34% [2] - The STAR Market Index is at 1812.33, up by 6.31 points or 0.35% [2] Sector Performance - AI applications and commercial aerospace themes experienced a pullback, while sectors such as memory storage, ultra-high voltage, medical services, precious metals, and AI wearable concepts were active [2] - Debon Securities resumed trading with a limit-up, as the company plans to voluntarily terminate its stock listing through a shareholder resolution [2] Company Highlights - Baiwei Storage opened over 9% higher, with a forecasted net profit increase of 427.19% to 520.22% year-on-year for 2025 [3][4] - Debon Securities saw a limit-up price of 15.44, reflecting a significant market interest following its announcement [3] Hong Kong Market - The Hang Seng Index opened 0.46% higher, with the Hang Seng Tech Index rising by 0.42% [4][5] - Notable gainers among constituent stocks include Haidilao, which rose over 5%, and Nongfu Spring, Hansoh Pharmaceutical, and China Biologic Products, which increased by over 3% [4][5]

Group 1 - The core point of the article is that China National Pharmaceutical Group announced a full acquisition of domestic siRNA innovative drug company Hejia Bio for a total price of 1.2 billion RMB, marking a significant move in the small nucleic acid sector [1] - The acquisition follows the company's previous investment in Saintin Bio, indicating a strategic focus on the small nucleic acid drug development space [1] - Hejia Bio is recognized as a pioneer in the research and development of small interfering RNA (siRNA) innovative drugs, with a comprehensive drug development system from target discovery to proof of concept (POC) [1] Group 2 - Hejia Bio is focused on three major chronic disease areas: weight loss metabolism, cardiovascular and cerebrovascular diseases, and neurological disorders [1] - The company possesses four clinical-stage assets and over ten preclinical assets, all of which have first-in-class and best-in-class potential [1]

Market Overview - The A-share market opened with a slight decline in the Shanghai Composite Index, while the Shenzhen Component Index, ChiNext Index, and Sci-Tech Innovation Board Index opened higher by 0.17%, 0.34%, and 0.35% respectively [3][4] - The market showed active trading in sectors such as memory storage, ultra-high voltage, medical services, precious metals, and AI wearable technology, while AI applications and commercial aerospace themes experienced a pullback [4] Individual Stocks - Debon Securities resumed trading with a limit-up increase, as the company plans to voluntarily terminate its stock listing through a shareholder resolution [5] - Baiwei Storage opened over 9% higher, with the company announcing a projected net profit increase of 427.19% to 520.22% year-on-year for 2025 [6][7] Hong Kong Market - The Hong Kong stock market opened with the Hang Seng Index rising by 0.46% and the Hang Seng Tech Index increasing by 0.42%. Notable gainers included Haidilao, which rose over 5%, and other companies like Nongfu Spring, Hansoh Pharmaceutical, and China Biologic Products, which saw increases of over 3% [8][9]

Market Overview - The A-share market opened with a slight decline in the Shanghai Composite Index, while the Shenzhen Component Index, ChiNext Index, and STAR Market Index opened higher by 0.17%, 0.34%, and 0.35% respectively [2][3] - The market saw active trading in sectors such as memory chips, ultra-high voltage, medical services, precious metals, and AI wearable concept stocks [3] Company Highlights - Debon Securities resumed trading with a limit-up increase, as the company plans to voluntarily terminate its stock listing through a shareholder resolution [3] - Baiwei Storage opened over 9% higher after announcing a projected net profit increase of 427.19% to 520.22% year-on-year for 2025 [5] Hong Kong Market - The Hang Seng Index opened up by 0.46%, with the Hang Seng Tech Index rising by 0.42% [6] - Notable gainers among constituent stocks included Haidilao, which rose over 5%, and Nongfu Spring, Hansoh Pharmaceutical, and China Biologic Products, which increased by over 3% [6]

Market Overview - The Hong Kong stock market opened higher on January 14, with the Hang Seng Index rising by 0.46% to 26,971.97 points, the Hang Seng Tech Index up by 0.42% to 5,894.63 points, the State-Owned Enterprises Index increasing by 0.46% to 9,328.05 points, and the Red Chip Index gaining 0.25% to 4,156.46 points [1] Company News - Q Technology (01478.HK) expects a net profit growth of approximately 400% to 450% for the year ending December 31, 2025 [2] - China Coal Energy (01898.HK) anticipates a 10.2% decrease in coal sales volume to approximately 256 million tons for 2025, with December sales down by 23% year-on-year to 21.88 million tons [2] - Zhixing Technology (01274.HK) has been selected as a supplier for a Korean automotive group's driver assistance solutions for four vehicle models [2] - Country Garden (00832.HK) projects a total property contract sales amount of 8.467 billion yuan for 2025, a decrease of 16.3% year-on-year [3] - Hopson Development (00754.HK) expects total contract sales of approximately 15.607 billion yuan for 2025, down 6.15% year-on-year [4] - Chuangjie Tong (01588.HK) anticipates a profit attributable to the parent company between 76 million and 85 million yuan for 2025, representing a year-on-year increase of 127% to 154% [4] - SUTENG (02498.HK) forecasts laser radar product sales of approximately 912,000 units for 2025 [5] - Xiaocaiyuan (00999.HK) plans to establish a joint venture to develop an online mall and "community ready-to-eat stores" [6] - GDS Holdings (09698.HK) has recovered approximately 95% of the investment principal from DayOne, with an investment return rate of nearly 6.5 times [7] - China Biologic Products (01177.HK) intends to acquire 100% of Hejiya for a maximum base price of 12 million yuan to accelerate the development of its siRNA liver delivery platform [7] - Innovent Biologics (02696.HK) has had its Biologics License Application for Hanbeitai® (Bevacizumab Injection) accepted by the FDA [7] - Xiaomi Group (01810.HK) repurchased 4 million shares for 152 million HKD at prices between 37.94 and 38.04 HKD [8] - Tencent Holdings (00700.HK) repurchased 1.012 million shares for 636 million HKD at prices between 623 and 638 HKD [9] - Sunny Optical Technology (02382.HK) repurchased 640,000 shares for 41.7878 million HKD at prices between 64.55 and 65.8 HKD [10] Institutional Insights - Dongwu Securities suggests that the window for the Federal Reserve to cut interest rates this year is limited, and the impact of fiscal policies on the economy is still forthcoming. If the Fed does not cut rates in the first quarter, the rebound pace of the Hong Kong stock market will depend more on fundamental factors. The overall allocation strategy for Hong Kong stocks remains a barbell strategy, recommending a controlled allocation while waiting for more news [11] - Wanlian Securities highlights that policy opinions indicate a push to accelerate the industrialization and commercialization of brain-computer interfaces. The global competitive landscape in this sector shows the U.S. leading in invasive methods while China leads in non-invasive methods, focusing on key elements such as electrodes, chips, and algorithms [11][12]